Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community.
作者信息
Cunningham Richard
机构信息
Department of Microbiology, Derriford Hospital, Plymouth, PL6 8DH, UK.
出版信息
CMAJ. 2006 Sep 26;175(7):757. doi: 10.1503/cmaj.060919.
Abstract
摘要
相似文献
1
Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community.质子泵抑制剂与艰难梭菌相关疾病的风险：来自社区的进一步证据。
CMAJ. 2006 Sep 26;175(7):757. doi: 10.1503/cmaj.060919.
2
Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.质子泵抑制剂的使用与因口服万古霉素治疗处方所定义的社区获得性艰难梭菌相关疾病的风险
CMAJ. 2006 Sep 26;175(7):745-8. doi: 10.1503/cmaj.060284.
3
Proton pump inhibitors and the risk for Clostridium difficile infection.
JAMA. 2009 Jul 1;302(1):31-2; author reply 32. doi: 10.1001/jama.2009.901.
4
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.使用胃酸抑制剂与社区获得性艰难梭菌相关疾病的风险
JAMA. 2005 Dec 21;294(23):2989-95. doi: 10.1001/jama.294.23.2989.
5
Gastric acid-suppressive agents and risk of Clostridium difficile-associated disease.胃酸抑制剂与艰难梭菌相关性疾病的风险
JAMA. 2006 Jun 14;295(22):2599-600; author reply 2600-1. doi: 10.1001/jama.295.22.2599-b.
6
Diagnosis and management of patients with Clostridium difficile-associated diarrhoea.艰难梭菌相关性腹泻患者的诊断与管理
Nurs Stand. 2007;21(46):49-56; quiz 58. doi: 10.7748/ns2007.07.21.46.49.c4589.
7
Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit.
Infect Control Hosp Epidemiol. 2007 Nov;28(11):1305-7. doi: 10.1086/521664. Epub 2007 Sep 18.
8
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.社区获得性艰难梭菌感染的流行病学，2009 年至 2011 年。
JAMA Intern Med. 2013 Jul 22;173(14):1359-67. doi: 10.1001/jamainternmed.2013.7056.
9
Increase in use of vancomycin for Clostridium difficile infection in US hospitals.美国医院中用于艰难梭菌感染的万古霉素使用量增加。
Infect Control Hosp Epidemiol. 2010 Aug;31(8):867-8. doi: 10.1086/655442.
10
Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis.共病、药物暴露与社区获得性艰难梭菌感染风险：一项系统评价和荟萃分析
Infect Control Hosp Epidemiol. 2015 Feb;36(2):132-41. doi: 10.1017/ice.2014.39.
引用本文的文献
1
Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.艰难梭菌感染与质子泵抑制剂在成人和儿科患者中的关联程度和方向：系统评价和荟萃分析。
J Gastroenterol. 2018 Jan;53(1):84-94. doi: 10.1007/s00535-017-1369-3. Epub 2017 Jul 25.
2
Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study.胃酸抑制与艰难梭菌感染结局的关系：基于人群的研究。
Mayo Clin Proc. 2012 Jul;87(7):636-42. doi: 10.1016/j.mayocp.2011.12.021.
本文引用的文献
1
Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.质子泵抑制剂的使用与因口服万古霉素治疗处方所定义的社区获得性艰难梭菌相关疾病的风险
CMAJ. 2006 Sep 26;175(7):745-8. doi: 10.1503/cmaj.060284.
2
Clostridium difficile-associated diarrhea outbreaks: the name of the game is isolation and cleaning.
Clin Infect Dis. 2006 Mar 1;42(5):725; author reply 727-9. doi: 10.1086/500264.
3
Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec.感染控制不力而非氟喹诺酮类药物，可能是魁北克艰难梭菌相关性腹泻暴发的主要原因。
Clin Infect Dis. 2006 Mar 1;42(5):725-7; author reply 727-9. doi: 10.1086/500268.
4
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.使用胃酸抑制剂与社区获得性艰难梭菌相关疾病的风险
JAMA. 2005 Dec 21;294(23):2989-95. doi: 10.1001/jama.294.23.2989.
5
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.艰难梭菌相关性腹泻的多机构主要克隆性暴发，发病率和死亡率高。
N Engl J Med. 2005 Dec 8;353(23):2442-9. doi: 10.1056/NEJMoa051639. Epub 2005 Dec 1.
6
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.氟喹诺酮类药物成为艰难梭菌相关性腹泻的主要危险因素：魁北克一次疫情期间的队列研究。
Clin Infect Dis. 2005 Nov 1;41(9):1254-60. doi: 10.1086/496986. Epub 2005 Sep 20.
7
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.1991年至2003年魁北克某地区艰难梭菌相关性腹泻：疾病严重程度的变化模式
CMAJ. 2004 Aug 31;171(5):466-72. doi: 10.1503/cmaj.1041104.
8
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.住院患者中开具质子泵抑制剂处方后发生艰难梭菌腹泻的风险：队列研究和病例对照研究
CMAJ. 2004 Jul 6;171(1):33-8. doi: 10.1503/cmaj.1040876.
9
Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001.1987 - 2001年美国医院获得性艰难梭菌病的长期趋势
J Infect Dis. 2004 May 1;189(9):1585-9. doi: 10.1086/383045. Epub 2004 Apr 20.
10
Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.质子泵抑制剂作为艰难梭菌腹泻的一个风险因素。
J Hosp Infect. 2003 Jul;54(3):243-5. doi: 10.1016/s0195-6701(03)00088-4.
Zotero 插件